FDA Clearance Tracker · P000029-S012
DEFLUX INJECTABLE GEL
Last checked: Nov 20, 2026Latest source record: Aug 2, 2005 (this decision)Source: openFDAMethods & limitations
Decided
Aug 2, 2005
Approved
Time to decision
116 days
Received Apr 8, 2005. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P000029-S012
- Device name
- DEFLUX INJECTABLE GEL
- Applicant
- Palette Life Sciences
- Applicant location
- Santa Barbara, CA
- Received
- Apr 8, 2005
- Decided
- Aug 2, 2005
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P000029
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR MODIFICATION OF THE POST APPROVAL STUDY PROTOCOL TO: 1) REPLACE THE 1- AND 5-YEAR VOIDING CYSTOURETHROGRAM MEASUREMENTS WITH CLINICAL ASSESSMENTS OF "FEBRILE UTI;" AND 2) DECREASE THE TOTAL SAMPLE SIZE FROM 200 TO 149 PATIENTS.
Source documents
Other decisions for Palette Life Sciences
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Barrigel Injectable Gel510(k)
K220641 · Decided May 26, 2022 · 83 days after receipt
Device type: Hydrogel Spacer (OVB) · Radiology & Imaging
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.